Trial Enrollment Watch — July 13–20, 2026

This week's scan of public ClinicalTrials.gov records identified 80 newly registered trials, along with 3 enrollment-distress indicators and 251 previously completed trials added to our rolling index of the overdue-results backlog. Below is what operations leaders should note before finalizing site lists or budget cycles.

New Registrations This Week

Oncology (25) and rare disease (30) led new registrations by volume, followed by immunology (8), cardiovascular and infectious disease (6 each), respiratory (2), and endocrine (2). Neurology had a single new registration this week. Several late-phase studies stood out for scale or sponsor profile:

NCT07712705 / NCT07712731 — Newsoara Biopharma, Psoriasis, Phase 3, 50 and 60 sites respectively
NCT07700979 — Akeso, Gastric/Gastroesophageal Junction Adenocarcinoma, Phase 3, 25 sites
NCT07710885 — Taiho Pharmaceutical, Biliary Tract Cancer, Phase 3, 21 sites
NCT07702578 — TScan Therapeutics, AML/MDS, Phase 3, 17 sites
NCT07697599 — Regeneron Pharmaceuticals, Venous Thromboembolism, Phase 3 (sites not yet listed)
NCT07700056 — Novartis Pharmaceuticals, Chronic Pruritus of Unknown Origin, Phase 3 (sites not yet listed)
NCT07700238 — Amgen, Primary Immune Thrombocytopenia, Phase 3 (sites not yet listed)
NCT07701993 — GlaxoSmithKline, Metabolic Dysfunction-associated Steatohepatitis, Phase 3 (sites not yet listed)

Enrollment-Distress Signals

Our heuristics flagged 3 enrollment-distress indicators this week, one each in infectious disease, neurology, and oncology. A low count in absolute terms, but worth tracking as a leading signal for site-level enrollment friction in these areas over coming weeks.

Overdue-Results Backlog

Our rolling index added 251 previously completed trials this week that remain more than 12 months past completion with no results posted. Rare disease (135) and oncology (67) accounted for the largest shares added, followed by immunology and neurology (13 each), cardiovascular (8), endocrine (7), infectious disease and respiratory (4 each). This scan draws from a standing backlog that FDA's March 2026 initiative sized at over 3,000 trials nationwide — our weekly additions reflect scan coverage, not a change in the underlying problem.

Site Selection Takeaway

Sponsors screening sites for the new Phase 3 psoriasis and gastric cancer programs above should weight prior results-reporting timeliness alongside historical enrollment velocity — a site's backlog history is a useful, underused proxy for future reporting risk.

Eichor generates free preliminary site-risk snapshots from public data for teams evaluating any of the trials listed above.

---

About these numbers. Individual trial facts — NCT IDs, sponsors, phases, site counts — come directly from ClinicalTrials.gov and can be verified there. Weekly totals, therapeutic-area breakdowns, enrollment-distress flags, and the overdue-results index are produced by Eichor's own daily registry scans and analysis heuristics; they are our measurements of public data, not statistics published by ClinicalTrials.gov or FDA. The 3,000-plus overdue-trials benchmark references FDA's March 2026 compliance reminders to 2,200-plus sponsors (FDA announcement). How we're built · How findings are signed.

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →
Launch offer through July 31: first full site unlock free — one per company.